(R)-1-Boc-3-氨甲基哌啶 | 140645-23-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (R)-1-Boc-3-氨甲基哌啶
• 中文别名: (R)-3-氨基甲基-1-N-BOC-哌啶；3-氨甲基哌啶-1-甲酸叔丁酯；(R)-3-氨基甲基-1-Boc-哌啶；(R)-1-叔丁氧羰基-3-氨甲基哌啶；(R)-3-氨基甲基-1-BOC-哌啶；R-1-BOC-3-氨甲基哌啶
• 英文名称: 1,1-dimethylethyl (3R)-3-(aminomethyl)-1-piperidinecarboxylate
• 英文别名: (R)-tert-butyl 3-(aminomethyl)piperidine-1-carboxylate；(3R)-3-aminomethyl-1-(tert-butoxycarbonyl)piperidine；tert-butyl (3R)-3-(aminomethyl)piperidine-1-carboxylate；(R)-1-Boc-3-(aminomethyl)piperidine；tert-butyl (R)-3-(aminomethyl)piperidine-1-carboxylate
• CAS: 140645-23-4
• 化学式: C₁₁H₂₂N₂O₂
• 分子量: 214.308
• InChiKey: WPWXYQIMXTUMJB-SECBINFHSA-N

物化性质

• 沸点：
  299.4±13.0 °C(Predicted)
• 密度：
  0.997g/mLat 25℃
• 闪点：
  >110°C

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R22,R50,R36/37/38
• 危险品运输编号：
  UN 3082 9 / PGIII
• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险标志：
  GHS07,GHS09
• 危险性描述：
  H302,H315,H319,H335,H400
• 危险性防范说明：
  P261,P273,P305 + P351 + P338

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
(R)-1-Boc-3-(aminomethyl)piperidine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
(R)-1-Boc-3-(aminomethyl)piperidine
Ingredient name:
CAS number: 140645-23-4

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H22N2O2
Molecular weight: 214.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

(R)-1-Boc-3-氨甲基哌啶是合成许多药物的重要中间体。研究人员以该化合物为原料，合成了多种检验点激酶 1 (Checkpoint Kinase 1, CHK1) 抑制剂，这些抑制剂对治疗类风湿病具有一定的疗效；同时，利用该化合物还开发了用于治疗由 MCH（黑素细胞刺激素）引起的疾病的药物系列，这类药物在治疗新陈代谢紊乱方面也显示出一定效果。此外，通过合成含有 1-N-Boc-4-甲氨甲基哌啶结构单元的 G-蛋白偶联受体 (G-protein coupled receptor, GPCR) 激动剂，可以用于治疗肥胖症和糖尿病；同时利用(R)-1-Boc-3-氨甲基哌啶还合成了调节新陈代谢、治疗心脏血管疾病的系列药物。

制备

以 3-哌啶乙酸为原料，通过酯化、还原、叔丁氧羰基保护、溴代、甲胺化五步反应，最终以 72% 的总收率合成了重要药物中间体 (R)-1-Boc-3-氨甲基哌啶。其合成路线图如下：

-1-Boc-3-氨甲基哌啶合成路线图)

反应信息

• 作为反应物：
  描述：

  (R)-1-Boc-3-氨甲基哌啶 在 三氟乙酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 68.5h， 生成 2-((S)-1-piperidin-3-ylmethyl)isoindole-1,3-dione
  参考文献：
  名称：

  [EN] PIPERIDINE AMIDES AS MODULATORS OF THE GHRELIN RECEPTOR
  [FR] PIPÉRIDINE-AMIDES EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA GHRÉLINE

  摘要：

  化合物的结构式（I）或其药学上可接受的盐，可用于治疗糖尿病和肥胖。

  公开号：

  WO2011117254A1
• 作为产物：
  描述：

  (S)-3-哌啶甲酸乙酯 在 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 sodium azide 、 palladium on activated charcoal 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 (R)-1-Boc-3-氨甲基哌啶
  参考文献：
  名称：

  신규한 트리아졸로 피라진 유도체 및 그의 용도

  摘要：

  该专利涉及一种新型的三唑基吡啶衍生物或其药学上可接受的盐，以及包含它们作为有效成分的用于抑制c-Met酪氨酸激酶活性的药学组合物，以及用于预防或治疗过度增殖性疾病（过度增殖性疾病）的药学组合物。该发明通过有效地抑制c-Met酪氨酸激酶的活性，可以有效地用于治疗与异常激酶活性导致的过度细胞增殖和生长有关的各种过度增殖性疾病，例如癌症、银屑病、类风湿关节炎、糖尿病性视网膜病变等。

  公开号：

  KR101745741B1

文献信息

• [EN] PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE-2,4-DIAMINE EN TANT QU'INHIBITEURS DE KINASE
  申请人：CELLZOME LTD

  公开号：WO2013092854A1

  公开（公告）日：2013-06-27

  The present invention relates to compounds of formula (I) wherein X, R, Y0, T0A, T0B have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immuno logically-mediated diseases. The invention also relates to pharmaceutical compositions including said compoundsand their use as medicaments.

  本发明涉及式(I)的化合物，其中X、R、Y0、T0A、T0B的含义如描述和权利要求中所述。所述化合物可用作JAK抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫学介导的疾病。该发明还涉及包括所述化合物的药物组合物及其作为药物的用途。
• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：Chin Elbert

  公开号：US20100081658A1

  公开（公告）日：2010-04-01

  Compounds having the formula I wherein R 1 , R 2a , R 2b , R 2c , R 3 , Y and p are as defined herein and C2-C3 is a single or double bond are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

  具有以下公式的化合物 I，其中 R1、R2a、R2b、R2c、R3、Y 和 p 的定义如本文所述，且 C2-C3 是单键或双键的化合物是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
• INHIBITORS OF INFLUENZA VIRUSES REPLICATION
  申请人：Charifson Paul S.

  公开号：US20120171245A1

  公开（公告）日：2012-07-05

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者中流感病毒的复制、减少生物样本或患者中流感病毒量以及治疗患者流感的方法，包括向所述生物样本或患者施用有效量的由结构公式（I）表示的化合物： 或其药用可接受盐，其中结构公式（IA）的值如本文所述。由结构公式（IA）或其药用可接受盐表示的化合物，其中结构公式（IA）的值如本文所述。药物组合物包括有效量的上述化合物或其药用可接受盐，以及药用可接受载体、佐剂或车辆。
• Inhibitors of influenza viruses replication
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US09345708B2

  公开（公告）日：2016-05-24

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者中流感病毒的复制、减少生物样本或患者中流感病毒量以及治疗患者流感的方法，包括向所述生物样本或患者施用结构式(I)表示的化合物的有效量： 或其药用可接受盐，其中结构式(IA)的值如本文所述。一种化合物由结构式(IA)或其药用可接受盐表示，其中结构式(IA)的值如本文所述。一种药物组合物包括这样的化合物或其药用可接受盐的有效量，以及药用可接受载体、佐剂或赋形剂。
• HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF
  申请人：CHOY Allison Laura

  公开号：US20100317624A1

  公开（公告）日：2010-12-16

  Compounds of formula (IA) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  公式（IA）的化合物及其药用可接受的盐被描述。还描述了它们的制备过程、含有它们的药物组合物、它们作为药物的使用以及它们在治疗细菌感染中的用途。